Aerie Pharmaceuticals Names Marvin J. Garrett as Vice President, Regulatory Affairs and Quality Assurance

Business Wire

BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.--(BUSINESS WIRE)--

Aerie Pharmaceuticals, Inc. (AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Marvin J. Garrett has been named Vice President, Regulatory Affairs and Quality Assurance of the Company. Mr. Garrett has nearly four decades of experience in the healthcare industry, having held senior leadership positions at many of the leading ophthalmology firms in the United States. During his career, Mr. Garrett spearheaded efforts gaining approval for over 45 marketing applications. His appointment at Aerie is effective immediately.

“Marvin brings a stellar track record with extensive knowledge pertaining to all areas of regulatory and FDA relations, quality, clinical research and operations and compliance within the ophthalmology space,” said Thomas Mitro, President and Chief Operating Officer at Aerie. “I have had the honor to work closely with Marvin in his previous roles at both ISTA and Allergan, and I know he will be an invaluable asset to our team.”

Mr. Garrett most recently served as Vice President, Regulatory Affairs, Quality and Compliance at Bausch + Lomb, Inc., following their acquisition of ISTA Pharmaceuticals, Inc., where he held the same position. During his more than decade-long tenure at ISTA, Mr. Garrett oversaw filings leading to five product approvals in the US. At the time of the Company’s acquisition, ISTA had grown to become the third largest branded prescription eye care business in the US. Previously, Mr. Garrett was Vice President, Regulatory Affairs, Clinical Research, Quality Assurance/Quality Compliance at XOMA, Ltd. Prior to this, he was President and Chief Executive Officer at CooperVision Pharmaceuticals and previously served as Vice President, Regulatory Affairs, Clinical Research, Quality Assurance/Control & Technical services at IOLAB Pharmaceuticals/Johnson & Johnson. Earlier in his career, Mr. Garrett held several positions at Allergan Pharmaceuticals, attaining the position of Director, US and International Regulatory Affairs. Mr. Garrett received his B.S. degree from California State University Long Beach and his M.A. degree in business management from the University of Redlands, California.

“I am delighted to be joining the exceptional Aerie team at this critical time in the advancement of the Company’s lead products,” stated Mr. Garrett. “There is a compelling need in glaucoma for therapies with distinctive mechanisms of action, as offered by the Company’s product candidates, and I look forward to Aerie’s lead program progressing into Phase 3 clinical testing.”

About Aerie Pharmaceuticals

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies. The Company is preparing for two Phase 3 registration trials, where the primary efficacy endpoint will be to demonstrate non-inferiority of IOP lowering for AR-13324 (dosed once daily) compared to timolol (dosed twice daily). In addition, the Company is conducting a Phase 2b clinical trial of its fixed-dose combination product PG324, where the primary efficacy endpoint will be to demonstrate superiority of PG324 to each of its components.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success, timing and cost of our ongoing clinical trials and anticipated Phase 3 and Phase 2b clinical trials for our current product candidates, including statements regarding the timing of initiation and completion of the trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect, to our product candidates; our estimates regarding anticipated capital requirements and our needs for additional financing; our expectations regarding the clinical effectiveness of our product candidates and results of our clinical trials; the potential advantages of our product candidates; our ability to protect our proprietary technology and enforce our intellectual property rights; and our expectations related to the use of proceeds from our initial public offering. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on regulatory approvals and economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading "Risk Factors" section contained in our final prospectus from our initial public offering which is on file with the Securities and Exchange Commission (SEC), and in the quarterly and annual reports that we file with the SEC. Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:
Aerie Pharmaceuticals
Richard Rubino, 908-470-4320
rrubino@aeriepharma.com
or
Burns McClellan, Inc. on behalf of Aerie Pharmaceuticals
Investors:
Angeli Kolhatkar, 212-213-0006
akolhatkar@burnsmc.com
or
Media:
Justin Jackson, 212-213-0006
jjackson@burnsmc.com

Rates

View Comments (0)